A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration

Shorter durations and lower doses of peg

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

✍ Y.-F. Liaw; J.-D. Jia; H.L.Y. Chan; K.H. Han; T. Tanwandee; W.L. Chuang; D.M. Ta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 1 views

As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared. HBeAg-p